The present invention relates to a process for providing a compound of formula (IV): ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently C.sub.1-C.sub.4 alkyl, and Hal is independently Cl or Br, the process comprising the steps of: (i) reacting a compound of formula (II) ##STR00002##
wherein R.sup.1 and Hal is defined as above, to obtain a compound of formula (III) ##STR00003##
wherein R.sup.1 and Hal is defined as above, and (ii) reacting the compound of formula (III) to obtain the compound of formula (IV).

The present invention relates to a process for providing a compound of formula (IV): ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently C.sub.1-C.sub.4 alkyl, and Hal is independently Cl or Br, the process comprising the steps of: (i) reacting a compound of formula (II) ##STR00002##
wherein R.sup.1 and Hal is defined as above, to obtain a compound of formula (III) ##STR00003##
wherein R.sup.1 and Hal is defined as above, and (ii) reacting the compound of formula (III) to obtain the compound of formula (IV).

The present invention relates to a process for providing a compound of formula (IV): ##STR00001##
wherein R.sup.1 and R.sup.2 are each independently C.sub.1-C.sub.4 alkyl, and Hal is independently Cl or Br, the process comprising the steps of: (i) reacting a compound of formula (II) ##STR00002##
wherein R.sup.1 and Hal is defined as above, to obtain a compound of formula (III) ##STR00003##
wherein R.sup.1 and Hal is defined as above, and (ii) reacting the compound of formula (III) to obtain the compound of formula (IV).

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

The present disclosure relates to the preparation of a highly pure cannabidiol compound by a novel synthesis route. The cannabidiol compound can be prepared by an acid-catalyzed reaction of a di-halo olivetol with menthadienol, followed by two crystallization steps. The highly pure cannabidiol compound is produced in high yield, stereospecificity, or both, and shows exceedingly low levels of -9-tetrahydrocannabinol at the time of preparation and after storage.

The present disclosure relates to the preparation of a highly pure cannabidiol compound by a novel synthesis route. The cannabidiol compound can be prepared by an acid-catalyzed reaction of a di-halo olivetol with menthadienol, followed by two crystallization steps. The highly pure cannabidiol compound is produced in high yield, stereospecificity, or both, and shows exceedingly low levels of -9-tetrahydrocannabinol at the time of preparation and after storage.

The present invention provides a preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine or a salt thereof, which uses 4-fluoro-3-methylphenol as the starting material, and is carried out through the steps of bromination, O-alkylation, cyclization, bromination, azidation or ammonolysis, and reduction. The reaction route of the present invention has simple synthesis process, convenient operation, high yield, and is environmentally friendly. The prepared (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine can be used as an intermediate in pharmaceuticals and fine chemicals.

The present invention provides a preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine or a salt thereof, which uses 4-fluoro-3-methylphenol as the starting material, and is carried out through the steps of bromination, O-alkylation, cyclization, bromination, azidation or ammonolysis, and reduction. The reaction route of the present invention has simple synthesis process, convenient operation, high yield, and is environmentally friendly. The prepared (5-fluoro-2,3-dihydrobenzofuran-4-yl)methylamine can be used as an intermediate in pharmaceuticals and fine chemicals.